HomeBUSINESS
BUSINESS

Kyowa Kirin License Novel Blood Cancer Treatment from US Company
(Nov.7.2018)

Kyowa Hakko Kirin said on November 5 that it has entered into a license agreement with MEI Pharma for the exclusive rights to develop and commercialize the US firm’s investigational phosphatidylinositol 3-kinase (PI3K) delta inhibitor ME-401 in Japan for the treatment of B-cell malignancies ...
(LOG IN FOR FULL STORY)